Multidisciplinary Precision and HIPEC Therapy Offer New Hope to 24-Year-Old Patient
Hyderabad, (Telangana) [India] April 21, 2025: Malla Reddy Narayana Cancer Hospital, Suraram, a premier cancer care centre in Telangana, held a press meet today at 11:30 AM within the hospital premises to announce a remarkable medical achievement: the successful treatment of a rare case of Primary Peritoneal Ewing’s Sarcoma using an advanced procedure involving Cytoreductive Surgery (CRS) followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
This rare and complex case involved 24-year-old Gautham Kumar, who had previously undergone two lines of chemotherapy at other institute, reached Malla Reddy Narayana Hospital for the Surgery. Diagnosed with Primary Peritoneal Ewing’s Sarcoma , an exceptionally rare and aggressive malignancy that typically does not occur in the peritoneum. The diagnosis and subsequent treatment required a high level of expertise and precision, provided by a multidisciplinary oncology team led by Dr. Harish Dara, Senior Consultant – Surgical Oncology
The surgical team undertook a challenging 16-hour procedure, which included complete tumor debulking followed by the direct infusion of heated chemotherapy into the abdominal cavity—a technique known as HIPEC. This innovative method is designed to eradicate any residual microscopic cancer cells, enhance chemotherapy absorption, and minimize damage to healthy tissues.
HIPEC, now available at Malla Reddy Narayana Cancer Hospital, represents a significant advancement in the treatment of abdominal cancers such as ovarian, colorectal, gastric cancers, pseudomyxoma peritonei, mesothelioma, and certain rare sarcomas. Unlike conventional chemotherapy, HIPEC is delivered intra-operatively at elevated temperatures, significantly improving clinical outcomes.
This successful case exemplifies the hospital’s ability to manage rare and complex oncological conditions through advanced medical technology, surgical expertise, and a patient-centric approach.
Quotes and Commentary
Dr. Ch. Bhadra Reddy , Chairman, Malla Reddy Vishwavidyapeeth, stated:
“This extraordinary case reflects our ongoing mission to bring advanced and accessible cancer care to the region. We continue to invest in infrastructure, technology, and expertise that allow us to manage even the rarest and most challenging cases with confidence and care.”
Dr. Ch. Preethi Reddy , Vice-Chairman, Malla Reddy Vishwavidyapeeth, stated:
“Treating Primary Peritoneal Ewing’s Sarcoma with advanced HIPEC is extremely rare—both globally and in India—due to the rarity of the disease and the specialized nature of the treatment. It demands highly skilled surgeons, specialized infrastructure, and a dedicated multidisciplinary team. Malla Reddy Narayana Cancer Hospital stands among India’s leading advanced cancer centres. We are proud to announce this success and I sincerely appreciate the commitment and excellence of our team of doctors.”
Dr. Harish Dara , Senior Consultant, Surgical Oncology, commented:
“This case represents the best of surgical innovation and team collaboration. When combined with complete cytoreduction, HIPEC can offer patients a real chance at long-term survival in situations where traditional treatment options fall short.”
Dr. G. Narendra Prakash , Senior Anaesthetist, shared:
“The success of this high-risk surgery required seamless coordination across multiple departments. Intraoperative stability was critical, and we ensured continuous monitoring and management throughout the extended duration of the procedure.”
About Malla Reddy Narayana Cancer Hospital
Located in Suraram, Hyderabad, Malla Reddy Narayana Cancer Hospital is a state-of-the-art oncology centre offering comprehensive cancer care. Through advanced diagnostics, expert multidisciplinary teams, and cutting-edge treatments such as HIPEC, the hospital remains at the forefront of personalized, precision-driven cancer therapy.
For more information, please contact:
Malla Reddy Narayana Cancer Hospital, Suraram, Hyderabad
Website: www.mallareddynarayana.com
Toll-Free: 87903 87903
